Although our paper focuses on the ability of AnxA5 to act as an immune checkpoint inhibitor against PS-induced tumor immune suppression, our findings also support the importance of potent, localized antigen-specific immune responses for effective cancer treatment. The gene discussed is ANXA5; the disease is cancer.